Self and community based opioid substitution among opioid dependent populations in the Indian sub-continent

International Journal of Drug Policy

Volumn 9, Issue 6, 1998, Pages 411-416

  Dorabjee, Jimmy D ^a   Samson, Luke J ^a  

^a Soc for Service to Urban Poverty   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0342926578     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3959(98)00057-7     Document Type: Article

References (19)

1. Bharadwaj, A. Self injecting of drugs gains popularity in Punjab, Times of India, 1 July, 1995.
2. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: dose-related blockade of opiod challenge effects in opiod dependent humans. Journal of Pharmocology and Experimental Therapeutics 1988;247(1):47-53.
3. Biswas S, et al. Hooked to a new high, India Today, April, 1994.
4. Crofts N. Global snapshot of HIV and IDU-presentation at workshop on harm reduction in NE India. Assam, October 1995.
5. Dorabjee J. IDU Reports. SHARAN Archives, 1994.
6. Eicher AD. IV drug use and HIV risks in Churachandpur; Manipur; India: a thesis presented to the Faculty of the Department of Epidemiology and Public Health, pp. 56-57, 66-67.
7. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opiod addiction II physiological and behavioural effects of daily and alternate day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics 1990;47(4):452-8.
8. INCB Report of the International Narcotics Control Board, 1996
9. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry 1978;35:501-16.
10. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of baprenorphine treatment for opioid dependence. Journal of the American Medical Association 1992;267(20):2750-5.
11. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opiod maintenance. Journal of Nervous and Mental Disease 1993;181(6):358-64.
12. Kumar, Daniels. HIV Risk Reduction Strategies among IDUs in Madras, 1994, CARITAS India, New Dehli.
13. Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependance 1990;26:19-28.
14. Lewis JW. Buprenorphine. Drug and Alcohol Dependence 1985;14:363-72.
15. Mello NK, Mendelson JH. Buprenorphine suppress heroin use by heroin addicts. Science 1980;207:657-9.
16. Mello NK, Mendelson JA, Kuehnle JC. Buprenorphine effects on human heroin self administration. An operant analysis. Journal of Pharmacology and Experimental Therapeutics. 1982;220:252-55.
17. Neil A. Affinities of some common opiod analgesics towards four binding sites in mouse brain, 1984. Naunyn-Schmiedebergs Naunyn-Schmiedebergs Archives of Pharmacology 328:24-9.
18. Panda S, Chatterjee A. Injecting drug use in calcutta: a potential focus for an explosive HIV epidemic. Drugs & Alcohol Review 1997;16(1):1997.
19. Shreshtra DM, Lohani J. Buprenorphine abuse in Nepal, 1995. Paper distributed at the WHO Drug Substitution Project meeting on opioid substitution programs in Asia, Kathmandu, Nepal 10-14 February, 1997.